To test the prognostic significance of ETS-related gene (ERG) expression in cytogenetically normal primary acute myeloid leukemia (AML).
INTRODUCTION
Cytogenetic abnormalities detected at diagnosis have long been recognized as predictors for clinical outcome in acute myeloid leukemia (AML). 1 However, the largest cytogenetic subset of adult AML, approximately 45%, consists of patients with a normal karyotype. 1 In large studies of the clinical significance of cytogenetics in AML, these patients have been categorized in an intermediate-risk group, with 5-year survival rates varying between 24% and 42%. [2] [3] [4] [5] The difference in clinical outcome likely reflects molecular heterogeneity of this cytogenetic subset whose prognosis is influenced by submicroscopic gene mutations or overexpression. 6 The adverse prognostic impact of the partial tandem duplication (PTD) of MLL, internal tandem duplication (ITD) of FLT3, and overexpression of BAALC in karyotypically normal AML is now established, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] as is the favorable prognostic significance of CEBPA gene mutations. 17, 18 However, it is likely that, in addition to the aforementioned genetic abnormalities, others will be found to impact on the clinical outcome of cytogenetically normal AML. Given that intensive treatments such as allogeneic stem-cell transplantation (SCT), although potentially curative in patients with poor prognosis AML, are associated with high treatment-related mortality, novel molecular markers will likely be valuable to stratify karyotypically normal AML patients to risk-adapted therapies. Furthermore, because these markers are mutated or overexpressed genes encoding proteins with potentially pivotal roles in leukemogenesis, they could also serve as molecular targets for novel therapeutic approaches. 19 We have recently shown that ETS-related gene (ERG), which is located at chromosome band 21q22, is frequently overexpressed in AML patients with complex karyotypes and cryptic amplification of chromosome 21. 20 ERG and other members of the ETS family are downstream effectors of mitogenic signaling transduction pathways and are involved in key steps regulating cell proliferation, differentiation, and apoptosis. [21] [22] [23] Although ERG rearrangements have been found in AML 24 and Ewing sarcoma 25 and its overexpression has been observed in prostate cancer, 26 little is known regarding how ERG contributes to malignant transformation. 27 In our previous report, 20 high ERG expression was not always associated with genomic amplification, thereby leaving ERG overexpression mechanistically unexplained. Nevertheless, the recurrent presence of ERG overexpression in AML with complex karyotypes, a prognostically unfavorable subgroup, suggests that ERG overexpression might not only be a nonrandom event in myeloid leukemogenesis, but also might contribute to an aggressive malignant phenotype.
To test this hypothesis, we analyzed karyotypically normal AML patients who were uniformly treated on the Cancer and Leukemia Group B (CALGB) 9621 protocol. 28 We show that the level of ERG expression varies among patients and that ERG overexpression constitutes an adverse prognostic factor in cytogenetically normal AML.
PATIENTS AND METHODS

Patients
ERG expression was analyzed in 84 adults aged less than 60 years with primary, untreated AML and normal cytogenetics confirmed by central morphologic and karyotype reviews. Eligible patients were enrolled onto the treatment trial CALGB 9621, 28 the prospective cytogenetic study CALGB 8461, 29 and the molecular study of BAALC expression (CALGB 9665).
15 Written institutional review board-approved informed consent was obtained from all patients.
Pretreatment cytogenetic analyses of bone marrow (BM) were performed as previously described. 4, 30 At least 20 metaphases were analyzed, and the karyotype was normal in each case. Pretreatment MLL PTD and FLT3 ITD status and BAALC levels were also determined centrally for each patient, as described previously.
7,10,15
Treatment
Patients received induction chemotherapy with cytarabine, daunorubicin, and etoposide with valspodar (PSC-833) or without valspodar. 28 On achievement of complete remission (CR), patients received high-dose etoposide and cytarabine for stem-cell mobilization followed by myeloablative treatment with busulfan and etoposide supported by autologous peripheral-blood SCT (APBSCT). Patients unable to receive APBSCT received two additional cycles of high-dose cytarabine. After consolidation, patients received maintenance with interleukin-2.
RNA Extraction and Real-Time Reverse Transcriptase Polymerase Chain Reaction
ERG expression was measured in blood for consistency with our previous analysis of the same patients characterized for BAALC expression. 15 Mononuclear cells from pretreatment blood were enriched by Ficoll-Hypaque gradient and cryopreserved in liquid nitrogen. Samples were chosen based on the availability of procured material with adequate RNA quality in the CALGB Leukemia Tissue Bank. Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA). cDNA synthesis and the real-time amplification reactions were performed as previously reported.
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The comparative cycle threshold (C T ) method was used to determine the relative expression levels of ERG to GPI, the internal control, in patients previously included in the BAALC expression study. 15 Of the original 86 patients, 84 were analyzed for ERG/GPI levels calculated using the mean of ⌬C T from two replicates and expressed as 2 (⌬CT) . The results of real-time reverse transcriptase polymerase chain reaction (RT-PCR) were correlated with clinical end points.
To assess the impact of ERG levels on clinical outcome, we also adopted an alternative approach. Absolute ERG copy numbers were measured and normalized to the copy numbers of ABL, which was a different internal control validated by multicenter studies, 31,32 using standard curves constructed as reported previously. 33 We analyzed 73 samples comprising 48 samples from patients included in the set evaluated for ERG/GPI levels and for whom leftover material was available and 25 samples from additional, karyotypically normal AML patients enrolled onto CALGB 9621. Importantly, eight of the latter patients had the unfavorable FLT3 ITD/Ϫ genotype, 10 the presence of which was a reason for exclusion from the previous BAALC study. 15 Positive and negative controls were included in all assays. The reproducibility of the real-time RT-PCR assays was similar to what we reported previously. ‫ء‬ P compares differences in presenting characteristics between patients with the three lowest quartiles and the highest quartile of ERG expression. †BAALC expression dichotomized at the median value.
use of the T7-Oligo(dT) primer (Affymetrix). In vitro transcription was performed with the BioArray HighYield RNA Transcript Labeling Kit (T7) (Enzo Life Science, Farmingdale, NY). Twenty micrograms of fragmented, biotinylated RNA was hybridized to the U133 plus 2.0 GeneChip for 16 hours at 45°C. Scanned images were converted to CEL files using GCOS software (Affymetrix).
Definition of Clinical End Points
CR was defined as recovery of morphologically normal BM and blood counts (ie, neutrophils Ն 1,500/L and platelets Ն 100,000/L) and no circulating leukemic blasts or evidence of extramedullary leukemia. Relapse was defined by more than 5% blasts in marrow aspirates or the development of extramedullary leukemia in patients with previously documented CR, according to National Cancer Institute criteria. 34 Cumulative incidence of relapse (CIR) was measured from the CR date to date of relapse, death, or date last known alive, where death in CR was considered a competing risk. Disease-free survival (DFS) was measured from the CR date until date of relapse or death (regardless of cause), censoring for patients alive at last follow-up. DFS was used only for the 73 patients analyzed for ERG/ABL because none of them died in CR, and therefore, DFS reflected the actual relapse risk. Overall survival (OS) was measured from the date the patient was enrolled onto the study until the date of death or date last known alive.
Statistical Methods
The main objective was to evaluate the impact of ERG expression on clinical outcome. A set of 84 patients was initially divided into quartile (Q) groups according to levels of ERG/GPI expression and subsequently dichotomized into groups including the three lower Qs (Q1, Q2, and Q3) and the upper Q (Q4) of ERG/ GPI values. Q4 was chosen for the cut point because the relapse risk was significantly different for the Q4 group compared with the Q1 (P ϭ .024), Q2 (P ϭ .002), and Q3 (P ϭ .009) groups. Similarly, the 73 patients characterized for ERG/ABL copy numbers in blood were dichotomized into Q1-3 and Q4 groups based on the number of normalized ERG copies. Pretreatment clinical features were compared between Q1-3 and Q4 groups using the Fisher's two-sided exact and Wilcoxon rank sum tests for categoric and continuous variables, respectively. 
Estimated probabilities of OS and DFS were calculated using the Kaplan-Meier method, and the log-rank test evaluated differences between survival distributions. Estimates of CIR were calculated, and Gray's k-sample test 35 evaluated differences in relapse rates. Proportional hazards models were constructed for OS and DFS, 36 whereas a multivariable model using Gray's method was constructed for CIR 37 using a limited backwards selection procedure. Variables remaining in the final models were significant at ␣ ϭ .05. Adjusted survival curves were generated from the proportional hazards and Gray models using average covariate values.
For microarray data analysis, normalization and modelbased expression index (MBEI) computations were performed using dChip version 1.3 (Harvard University, Cambridge, MA).
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Only the perfect match probes were used in the computation of MBEIs, whereas mismatch probes were ignored. Log[MBEI] values were calculated and then exported to BRB-ArrayTools v3.2.3 (National Cancer Institute, Bethesda, MD) for further analysis. Probe sets with a variance in log[MBEI] values above the 80th percentile were retained for further analyses (n ϭ 10,935). A comparison of gene expression between Q1-3 and Q4 was performed by two-sample t tests using ␣ ϭ .001 as the significance level, which would result in approximately 11 expected false discoveries assuming no gene expression differences between the two groups. A permutation test was performed to validate the results of the parametric test. All analyses were performed by the CALGB Statistical Center.
RESULTS
Impact of ERG Expression on Clinical Outcome
No significant differences were observed in most pretreatment clinical characteristics between patients with the lowest 75% (Q1-3) and highest 25% (Q4) of ERG expression values. The two groups differed for BAALC expression levels (P ϭ .042), circulating (P ϭ .045) and BM (P ϭ .056) blast percentages, gum hypertrophy (P ϭ .060), and FrenchAmerican-British subgroup distribution (P ϭ .023; Table 1 ).
The CR rate was 81%, with no significant difference between patients in Q4 and Q1-3 (P ϭ .532; Table 2 ). With a median follow-up of 5.7 years (range, 4.4 to 7.4 years), patients in Q4 had a worse CIR than patients in Q1-3 (P Ͻ .001; Fig 1A) . The estimated 5-year relapse rate for Q4 patients was 81% compared with 33% for Q1-3 patients (Table 2) . Furthermore, the OS was different between the two groups (P ϭ .011; Fig 1B) . Patients in Q4 had a median survival time of 1.2 years and an estimated 5-year survival rate of 19%; in contrast, median survival time for Q1-3 patients has not been reached, and their estimated 5-year survival rate was 51% (Table 2 ). When analysis was restricted to the set of patients who achieved CR and received APBSCT as a prescribed consolidation treatment (n ϭ 49), ERG remained a significant adverse factor for outcome (data not shown).
On multivariable analysis, high ERG expression (ie, Q4) adversely impacted CIR (P Ͻ .001), as did the presence of MLL PTD (P ϭ .027; Table 3 , Fig 2A) . Patients in Q4 had an estimated relapse risk almost four times higher than patients in Q1-3. For OS, an interaction between expression of ERG and BAALC (P ϭ .013) was observed (Table 3) . For low BAALC levels, patients in Q4 had a shorter survival than patients in Q1-3 (P ϭ .002; Fig 2B, Table 3 ). However, the adverse impact of high ERG expression on OS was not observed in patients with high BAALC expression (P ϭ .922; Fig 2C, Table 3 ). The only patients who maintained a longterm survival rate greater than 50% were patients with lower expression of both ERG and BAALC. Additionally, worse survival was associated with higher log[WBC] (P ϭ .012; Table 3 ). Although Q4 patients had a higher percentage of circulating blasts at diagnosis (Table 1) , this factor did not impact significantly on clinical outcome and, consequently, was not included in the multivariable models.
Similar results were obtained when we used a second analytic strategy uing specific standard curves to measure ERG copy numbers normalized to ABL. 32, 33 To explore whether ERG expression predicts clinical outcome independently from other major unfavorable prognostic markers, we included samples with the most unfavorable FLT3 genotype, FLT3 ITD/Ϫ . Normalized ERG copies ranged from 0.4 to ) and presence of MLL PTD. †High and low BAALC groups defined by a cut point taken at the median BAALC expression value. 735.9 (median, 17.9 copies). Patients with the lowest 75% (Q1-3; n ϭ 55) of ERG copies (median, 11.0 copies; range, 0.4 to 35.1 copies) were compared with patients with the highest 25% (Q4; n ϭ 18) of ERG copies (median, 62.2 copies; range, 37.5 to 735.9 copies). There were no significant differences in FLT3 genotype distribution, which included wild-type FLT3 (FLT3 ; P ϭ .644). Patients in Q4 had a worse DFS (P ϭ .092) and OS (P ϭ .003) than patients in Q1-3, with an estimated 5-year DFS of 25% (95% CI, 6% to 50%) v 53% (95% CI, 38% to 66%), respectively, and OS of 22% (95% CI, 7% to 43%) v 54% (95% CI, 40% to 67%), respectively. When the analysis was restricted to the subset of 25 patients not analyzed for ERG/GPI, ERG overexpression remained a significant adverse predictor for both OS and DFS (data not shown).
In a multivariable model, high ERG copy number (ie, Q4; P ϭ .023; Fig 3A) and FLT3 ITD (P Ͻ .001) independently predicted worse DFS. The estimated relapse risk for Q4 patients was more than twice the risk for Q1-3 patients (hazard ratio [HR] ϭ 2.55; 95% CI, 1.14 to 5.69 
Gene Expression Profiling by Oligonucleotide Microarrays in High Versus Low ERG
Microarray gene expression profiling was conducted to assess whether ERG overexpression was associated with a specific signature suggestive of the gene's potential leukemogenic role. One hundred seventeen probes in the Affymetrix U133 plus 2.0 GeneChip were differentially expressed (P Ͻ .001) between the Q1-3 and Q4 groups, including 63 unique, named genes and 49 expressed-sequenced tags. Twenty-five probes corresponding to 14 named genes (Table 4) and eight expressed-sequenced tags had at least a two-fold difference in expression levels between the Q1-3 and Q4 groups (Fig 4) . Supporting our real-time RT-PCR results, three probe sets for ERG were differentially expressed, with average expression 2.1 to 2.6 times higher in Q4 patients.
Of the 63 named genes overexpressed in Q4, functional characterization was available for 53. Twenty-three of the genes are involved in DNA and/or RNA binding and chromatin remodeling, including general transcription activators (ie, GTF2H2, FAM48A, TCF12, and GCN5L2) or repressors (CTBP2) and lineage-specific transcription regulators, such as BCL11A, which is involved in lymphoid cell development, 41 and HEMGN, which is involved in myeloid differentiation. [42] [43] [44] Other genes encode small GTPases, members of the RAS superfamily (RALA and RAB10) or their regulators (RABGAP1 and ARHGAP22), or proteins involved in membrane-receptor signaling pathways (GPR21, DPAGT1, PILRB, GPR89, and FRMD4B), including activators of small GTPases. Surprisingly, we found overexpression of three proapoptotic genes (PACAP, IKIP, and DAPK1); DAPK1 was recently reported to be silenced by methylation in AML. 45 Finally, the following three genes with unknown function but linked to hereditary diseases were upregulated: ATXN2, which is mutated in autosomaldominant spinocerebellar ataxia-2, 46 SHANK3, which is involved in the 22q13 deletion syndrome, 47 and OFD1, which is mutated in orofaciodigital syndrome I. 48 To our knowledge, overexpression or mutations of these genes have hitherto not been reported in AML.
DISCUSSION
Although molecular mechanisms underlying diverse clinical outcome in cytogenetically normal AML are not fully understood, recent studies have identified several biomarkers correlated with prognosis. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Here, we report for the first time that ERG overexpression predicted an increased relapse risk and short survival in AML patients with normal karyotype by both univariable and multivariable analyses. Despite a relatively small number of patients studied, our data support the addition of ERG overexpression to the emerging list of markers predictive for clinical outcome in cytogenetically normal AML.
With the number of prognostic markers growing, the relative contribution of each in predicting treatment outcome becomes important. In the current study, although high ERG levels correlated with an increased relapse risk regardless of the BAALC expression, a prognostic interaction between ERG and BAALC expression was observed for OS, with a shorter survival associated with high ERG levels only among patients with low BAALC expression. Likewise, interactions among prognostic markers, such as a greater prognostic importance of FLT3 ITD compared with BAALC overexpression and of BAALC overexpression compared with CEBPA mutations, have been reported previously. 15, 17, 18 Because data on the impact of the concurrent presence of two or more molecular markers in cytogenetically normal AML are limited, further investigation of prognostic interactions is required by large prospective studies, with the goal of designing a prioritized, clinically relevant prognostic classification.
Although our data suggest that expression of ERG is useful for prognostic stratification of cytogenetically normal AML, the mechanism through which ERG overexpression contributes to myeloid leukemogenesis remains unknown. ERG is one of more than 30 members of the ETS gene family, most of which are downstream nuclear targets of signal transduction pathways regulating and promoting cell differentiation, proliferation, and tissue invasion. 21, 22, 27 Rearrangement of ERG was initially discovered in Ewing sarcomas harboring t(21;22)(q22;q12), which at the molecular level fuses ERG with EWS. 25 Other ETS family members also fuse with EWS in Ewing sarcomas. [49] [50] [51] In AML carrying t(16;21)(p11;q22), ERG was found rearranged with FUS, linking ERG with myeloid leukemogenesis for the first time. 24 Interestingly, like EWS, FUS is a member of the TET family of RNA-binding proteins, 52 supporting the notion that gene rearrangements involving ETS members are often characterized by a TET-related transactivation domain at the N terminus and ETS DNA binding and protein-protein interaction domains at the C terminus. This structure likely increases the oncogenic activity of the resulting chimeric transcription factors by redirecting them to specific targets. Interestingly, a role for ERG in endothelial cell differentiation and angiogenesis was recently suggested. 23, 53 Our microarray gene expression profiling analysis, using a supervised analysis, identified a molecular signature for patients in the highest Q (Q4) of ERG expression. Many genes upregulated in Q4, including ERG, encode proteins functioning as transcription factors or involved in chromatin remodeling and RNA processing; others encode proteins regulating cell differentiation, proliferation, and apoptosis. Interestingly, the recently described HEMGN gene (also known as EDAG) was the most differentially expressed gene between the two groups. This gene reportedly regulates proliferation, differentiation, and apoptosis of hematopoietic cells and seems to be significantly overexpressed in refractory AML patients but not in patients with chemotherapy-sensitive disease.
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Because the molecular signature for the ERG overexpressers was defined by patients' clustering based on previously identified prognostic groups (ie, Q4 v Q1-3), it was not surprising that this gene profile was associated with a worse clinical outcome (data not shown). Obviously, for ERG expression to become a molecular marker used routinely for risk stratification in AML with normal cytogenetics, our data require confirmation in an independent, large patient cohort.
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